These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 395068)

  • 1. The artificial beta cell (Biostator) in the adjustment of instable diabetics--results after 20 months.
    Beyer J; Wolf E; Cordes U; Hassingen W
    Horm Metab Res Suppl; 1979; (8):127-31. PubMed ID: 395068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of cortisol circadian variations on insulin need and delivery in insulin-dependent diabetics. Assessment by the artificial beta cell.
    Altomare E; Moulin JP; Tavares S; Bourelly N; Lassmann V; Vague P
    Horm Metab Res Suppl; 1979; (8):110-5. PubMed ID: 395065
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of daily insulin requirements in diabetics with an artificial endocrine pancreas.
    Lambert AE; Buysschaert M; Lambotte L
    Horm Metab Res Suppl; 1979; (8):120-7. PubMed ID: 395067
    [No Abstract]   [Full Text] [Related]  

  • 4. Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
    Christiansen JS; Svendsen PA; Deckert T
    Horm Metab Res Suppl; 1979; (8):131-4. PubMed ID: 395069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control algorithms for artificial beta cell.
    Clemens AH
    Horm Metab Res Suppl; 1979; (8):35-8. PubMed ID: 395086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of a perfusion syringe (Mill Hill Infusor) and a glucose-controlled insulin infusion system in the regulation of diabetes mellitus.
    Stavljenić A; Granić M; Topić B; Skrabalo Z
    Horm Metab Res Suppl; 1979; (8):207-11. PubMed ID: 395083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal blood sugar control in labile diabetics using a portable open-loop insulin infusion system with a flexible program.
    Froesch ER; Blatter G; Morell B
    Horm Metab Res Suppl; 1979; (8):198-201. PubMed ID: 395079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a closed-loop artificial pancreas.
    Kraegen EW; Whiteside R; Bell D; Chia YO; Lazarus L
    Horm Metab Res Suppl; 1979; (8):38-42. PubMed ID: 395087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of an artificial beta cell in surgery.
    Horwitz DL; Schwartz SS
    Horm Metab Res Suppl; 1979; (8):156-8. PubMed ID: 395072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutical application of artificial beta-cell in surgery and obstetrics.
    Brunetti P; Puxeddu A; Calabrese G; Massi-Benedetti M; Santeusanio F; Bolli G; Scionti L; Bueti A; Angeletti G
    Horm Metab Res Suppl; 1979; (8):162-5. PubMed ID: 395074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood glucose monitoring and computer regulation by means of an artificial endocrine pancreas.
    Kruse-Jarres JD; Braun G; Naegele R; Bresch M; Lehmann U
    Horm Metab Res Suppl; 1979; (8):42-5. PubMed ID: 395088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic study of the blood viscosity of insulin-dependent diabetics by means of an artificial pancreas.
    Drouin P; Rousselle D; Pointel JP; Voisin G; Stoltz JF; Clemens AH; Debry G
    Horm Metab Res Suppl; 1979; (8):107-10. PubMed ID: 395064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical application of pre-programmed insulin infusion: continuous subcutaneous insulin therapy with a portable infusion system.
    Pickup JC; Viberti GC; Keen H; Parsons JA; Alberti KG
    Horm Metab Res Suppl; 1979; (8):202-4. PubMed ID: 395081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of glucose-controlled insulin infusion system for improvement of subcutaneous insulin regimen.
    Irsigler K; Kritz H; Kaspar L; Brändle J; Franetzki M
    Horm Metab Res Suppl; 1979; (8):134-40. PubMed ID: 395070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of insulin infusion kinetics of an artificial beta cell on blood glucose control in insulin-dependent diabetics.
    Kerner W; Beischer W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):71-80. PubMed ID: 395094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics.
    Schock A; Schultz M; Kerner W; Maier V; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):93-6. PubMed ID: 395097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closed-loop system in evaluation of insulin infusion rates for an open-loop system.
    Kølendorf K; Christiansen JS; Svendsen PA; Bojsen J
    Horm Metab Res Suppl; 1979; (8):205-6. PubMed ID: 395082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The external artificial pancreas: an instrument to induce remissions in severe recent juvenile diabetes. Comparison with a preprogrammed insulin infusion system.
    Mirouze J; Selam JL; Pham TC; Orsetti A
    Horm Metab Res Suppl; 1979; (8):141-5. PubMed ID: 395071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intravenous insulin therapy with a miniaturized open-loop system.
    Renner R; Hepp KD; Mehnert H; Franetzki M
    Horm Metab Res Suppl; 1979; (8):186-90. PubMed ID: 395077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of an artificial endocrine pancreas in the management of the diabetic surgical patient.
    Kerner W; Beischer W; Herfarth C; Pfeiffer EF
    Horm Metab Res Suppl; 1979; (8):159-61. PubMed ID: 395073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.